FDA Cites Genus Lifesciences for Failure to Source Contaminants

Drug Industry Daily
A A
The FDA hit Genus Lifesciences with a Form 483 following a July inspection of its Allentown, Pa., drug facility, citing inadequate reviews of discrepancies and failure to reject substandard products.

To View This Article:

Login

Subscribe To Drug Industry Daily